Friday 6 November 2026 Export KYMR’s income statement to Excel — free account

Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $39.2 million, down 16.7% from fiscal 2024.

Revenue: +466.4%
EPS: −40.3%
Free cash flow: −186.6%
Total debt: −66.6%

Quarter to September 2026, against a year earlier

Insider buying

132.01 3.89 +3.04%

Follow KYMR

Alert me

Market cap: $10.9B
P/E: 0.0×
Fwd P/E: −31.6×
Dividend yield: —
F-score: 4/9
Altman Z: 23.22
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Valuation Filings

Kymera Therapeutics, Inc. (KYMR) Debt to equity

Alert me on Debt to equity

Kymera Therapeutics, Inc.'s debt to equity at the end of the quarter to 30 September 2026 was 0.0×, down 0.0× from fiscal 2025 (0.0×). Over the past ten years it has ranged from 0.0× (fiscal 2025) to 0.0× (fiscal 2019) — the current reading is the lowest in ten years. That is above the Biotechnology industry median of 0.0× and above the Healthcare sector median of 0.0×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/KYMR/debt-to-equity" width="100%" height="360" style="border:0" loading="lazy" title="Kymera Therapeutics, Inc. debt to equity, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/KYMR/metrics/debt-to-equity">Kymera Therapeutics, Inc. (KYMR) debt to equity — stockrow.com</a></p>

Period	Debt to equity	Change
FY2025	0.0×	(66.67%)
FY2024	0.0×	(18.18%)
FY2023	0.0×	32.00%
FY2022	0.0×	0.00%
FY2021	0.0×	19.05%
FY2020	0.0×	(93.75%)
FY2019	0.0×	88.76%
FY2018	0.0×	—

Period	Debt to equity	Change
Sep 2026	0.0×	(33.33%)
Jun 2026	0.0×	(14.29%)
Mar 2026	0.0×	(22.22%)
Dec 2025	0.0×	(52.63%)
25 more quarters	Free account

Against its own ten years

Low 0.0× High 0.0×

Ten-year median 0.0×

Current reading's percentile 13

Company	Debt to equity
IBRX ImmunityBio, Inc. compare	−0.7×
CAI Caris Life Sciences,�Inc. compare	0.0×
SMMT Summit Therapeutics PLC compare	0.0×
PCVX Vaxcyte, Inc. compare	0.0×
KYMR Kymera Therapeutics, Inc.	0.0×
TWST Twist Bioscience Corporation compare	0.0×
TECH Bio-Techne Corp compare	0.1×
BMRN BioMarin Pharmaceutical Inc. compare	0.7×
TGTX TG Therapeutics, Inc. compare	1.2×
Biotechnology industry median	0.0×
Healthcare sector median	0.0×
Market median	0.1×

What Debt to equity is

Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.

(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)

The full definition of Debt to equity →

Kymera Therapeutics, Inc. (KYMR) Debt to equity

Debt to equity, annual

Annual newest first

Quarterly newest first

Against its own ten years

Debt to equity against peers

What Debt to equity is

More on KYMR

Debt to equity, annual

Annual newest first

Quarterly newest first

Against its own ten years

Debt to equity against peers

What Debt to equity is

More on KYMR

Stockrow Weekly